Embecta (NASDAQ:EMBC) Stock Rating Upgraded by Wall Street Zen

Embecta (NASDAQ:EMBC) was upgraded by Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

Several other equities analysts have also recently weighed in on the stock. BTIG Research reiterated a “buy” rating and set a $25.00 price objective on shares of Embecta in a research report on Friday, February 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Embecta in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $18.50.

Embecta Trading Down 3.9%

EMBC stock opened at $9.07 on Friday. Embecta has a one year low of $9.06 and a one year high of $15.55. The firm has a 50-day moving average of $11.08 and a two-hundred day moving average of $12.76. The firm has a market capitalization of $537.13 million, a PE ratio of 3.83 and a beta of 1.10.

Embecta (NASDAQ:EMBC) last released its earnings results on Thursday, February 5th. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.04. Embecta had a net margin of 12.92% and a negative return on equity of 26.66%. The business had revenue of $261.20 million for the quarter, compared to the consensus estimate of $258.07 million. During the same period last year, the firm posted $0.65 earnings per share. The firm’s quarterly revenue was down .3% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 2.800-3.00 EPS. On average, equities research analysts anticipate that Embecta will post 2.85 earnings per share for the current year.

Institutional Investors Weigh In On Embecta

A number of large investors have recently added to or reduced their stakes in EMBC. Alpine Global Management LLC acquired a new position in shares of Embecta during the 4th quarter worth about $178,000. River Road Asset Management LLC grew its holdings in Embecta by 5.3% in the 4th quarter. River Road Asset Management LLC now owns 3,416,401 shares of the company’s stock valued at $40,587,000 after buying an additional 171,194 shares during the last quarter. Pacer Advisors Inc. grew its holdings in Embecta by 49.3% in the 4th quarter. Pacer Advisors Inc. now owns 16,526 shares of the company’s stock valued at $196,000 after buying an additional 5,460 shares during the last quarter. State of Tennessee Department of Treasury increased its position in Embecta by 23.9% in the 4th quarter. State of Tennessee Department of Treasury now owns 53,290 shares of the company’s stock worth $633,000 after buying an additional 10,263 shares during the period. Finally, Mackenzie Financial Corp increased its position in Embecta by 34.0% in the 4th quarter. Mackenzie Financial Corp now owns 135,085 shares of the company’s stock worth $1,627,000 after buying an additional 34,240 shares during the period. Institutional investors own 93.83% of the company’s stock.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.